Bicycle Therapeutics plc American Depositary Shares (BCYC)

Bicycle Toxin Conjugates (BTCs) are emerging as a novel targeted oncology technology, offering innovative peptide-based drug delivery with potential applications in cancer treatment and beyond, with early clinical trials showing promising results.

Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Twist Bioscience (TWST) have performed compared to their sector so far this year.

During the last three months, 4 analysts shared their evaluations of Bicycle Therapeutics (NASDAQ:BCYC), revealing diverse outlooks from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Bicycle Therapeutics, revealing an average target of $50.25, a high estimate of $60.00, and a low estimate of $43.00. A 11.84% drop is evident in the current average compared to the previous average price target of $57.00. Understanding Analyst Ratings: A Comprehensive Breakdown The perception of Bicycle Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Ami Fadia Needham Maintains Buy $43.00 - Bill Maughan Canaccord Genuity Maintains Buy $60.00 - Swayampakula Ramakanth HC Wainwright & Co. Lowers Buy $55.00 $57.00 Ami Fadia Needham Maintains Buy $43.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bicycle Therapeutics. This information offers a ...Full story available on Benzinga.com

The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy.